GUSELKUMAB, AN ANTI-INTERLEUKIN-23P19-SUBUNIT MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO WERE BIOLOGIC-NAIVE OR PRIOR TNFα INHIBITOR-TREATED: WEEK 24 RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

被引：0

作者：

Deodhar, Atul ^{[1
]}

Helliwell, Philip ^{[2
]}

Boencke, Wolf-Henning ^{[3
]}

Hsia, Elizabeth C. ^{[4
,5
,6
]}

Kollmeier, Alexa P. ^{[4
,5
]}

Subramanian, Ramanand A. ^{[4
,5
]}

Xu, Xie L. ^{[4
,5
]}

Sheng, Shihong ^{[4
,5
]}

Zhou, Bei ^{[4
,5
]}

Zazzetti, Federico ^{[7
]}

Ritchlin, Christopher ^{[8
]}

机构：

[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[2] Univ Leeds, Leeds, W Yorkshire, England

[3] Geneva Univ Hosp, Geneva, Switzerland

[4] Janssen Res & Dev LLC, Spring House, PA USA

[5] Janssen Res & Dev LLC, San Diego, CA USA

[6] Univ Penn, Med Ctr, Philadelphia, PA 19104 USA

[7] Janssen LATAM Med Affairs, Buenos Aires, DF, Argentina

[8] Univ Rochester, Med Ctr, Rochester, NY 14642 USA

来源：

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2020年 / 26卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

298

引用

页码：24 / 24

页数：1

共 50 条

[11] Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19-Subunit of Interleukin-23, Through 2 Years: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naive Patients with Active Psoriatic Arthritis
McInnes, Iain
Rahman, Proton
Gottlieb, Alice
Hsia, Elizabeth
Kollmeier, Alexa
Xu, Xie
Sheng, Shihong
Jiang, Yusang
Shawi, May
Chakravarty, Soumya
van der Heijde, Desiree
Mease, Philip
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2777 - 2779
[12] LOW RATES OF RADIOGRAPHIC PROGRESSION WITH 2 YEARS OF GUSELKUMAB, A SELECTIVE INHIBITOR OF THE INTERLEUKIN-23P19 SUBUNIT: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
Mease, P. J.
Gottlieb, A. B.
Mcinnes, I.
Rahman, P.
Kollmeier, A.
Xu, X. L.
Jiang, Y.
Sheng, S.
Shawi, M.
Chakravarty, S. D.
Lavie, F.
Van der Heijde, D.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 831 - 832
[13] Low Rates of Radiographic Progression with 2 Years of Guselkumab (TREMFYA®), a Selective Inhibitor of the Interleukin-23p19 Subunit: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study of Biologic-naive Patients with Active Psoriatic Arthritis
Mease, Philip
Gottlieb, Alice
McInnes, Iain
Rahman, Proton
Kollmeier, Alexa
Xu, Xie
Jiang, Yusang
Sheng, Shihong
Shawi, May
Chakravarty, Soumya
Lavie, Frederic
van der Heijde, Desiree
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3763 - 3765
[14] Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
Deodhar, Atul
Helliwell, Philip S.
Boehncke, Wolf-Henning
Kollmeier, Alexa P.
Hsia, Elizabeth C.
Subramanian, Ramanand A.
Xu, Xie L.
Sheng, Shihong
Agarwal, Prasheen
Zhou, Bei
Zhuang, Yanli
Ritchlin, Christopher T.
LANCET, 2020, 395 (10230): : 1115 - 1125
[15] EFFICACY AND SAFETY-OF GUSELKUMAB, A NIONOCLONAL ANTIBODY SPECIFIC TO THE P19-SUBUNIT OF INTERLEUKIN-23, THROUGH 2YEARS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
Soriano, Enrique R.
Mcinnes, Iain B.
Rahman, Proton
Gottlieb, Alice R.
Hsia, Elizabeth C.
Kollmeier, Alexa P.
Xu, Xie L.
Sheng, Shihong
Jiang, Yusang
Shawi, May
Chakravarty, Soumya A.
Van der Heijde, Desiree
Mease, Philip J.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 : S93 - S93
[16] Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis
McInnes, Iain B.
Rahman, Proton
Gottlieb, Alice B.
Hsia, Elizabeth C.
Kollmeier, Alexa P.
Xu, Xie L.
Jiang, Yusang
Sheng, Shihong
Shawi, May
Chakravarty, Soumya D.
van der Heijde, Desiree
Mease, Philip J.
ARTHRITIS & RHEUMATOLOGY, 2022, 74 (03) : 475 - 485
[17] Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
Mease, Philip J.
Rahman, Proton
Gottlieb, Alice B.
Kollmeier, Alexa P.
Hsia, Elizabeth C.
Xu, Xie L.
Sheng, Shihong
Agarwal, Prasheen
Zhou, Bei
Zhuang, Yanli
van der Heijde, Desiree
McInnes, Iain B.
LANCET, 2020, 395 (10230): : 1126 - 1136
[18] EFFICACY AND SAFETY OF GUSELKUMAB IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE AXIAL PSORIATIC ARTHRITIS: STUDY DESIGN OF A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Gladman, D. D.
Mease, P. J.
Bird, P.
Soriano, E.
Chakravarty, S. D.
Shawi, M.
Xu, S.
Quinn, S.
Gong, C.
Leibowitz, E.
Tam, L. S.
Helliwell, P.
Kavanaugh, A.
Deodhar, A.
Ostergaard, M.
Baraliakos, X.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1574 - 1575
[19] Efficacy and safety of Guselkumab through 2 years: Results from a phase 3, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis
McInnes, I.
Rahman, P.
Gottlieb, A.
Hsia, E.
Kollmeier, A.
Xu, X.
Sheng, S.
Jiang, Y.
Shawi, M.
Chakravarty, S.
van der Heijde, D.
Mease, P.
EXPERIMENTAL DERMATOLOGY, 2021, 30 : 38 - 38
[20] EFFICACY AND SAFETY RESULTS OF GUSELKUMAB, AN ANTI-IL23 MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS OVER 24 WEEKS: A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Deodhar, A.
Gottlieb, A.
Boehncke, W. -H.
Dong, B.
Wang, Y.
Barchuk, W.
Xu, X. L.
Hsia, E.
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 142 - 143

← 1 2 3 4 5 →